Freshness note: This analysis was last updated 28 days ago. Fast-moving policy claims can change quickly, so check for newer official updates before relying on this verdict.
“Trump administration reversed cost caps Biden negotiated for Medicare and Medicaid prescription drugs”
Summary
Trump signed an executive order in January 2025 that paused some Biden-era drug pricing regulations, but did not reverse the negotiated Medicare prescription drug price caps established under the Inflation Reduction Act. The negotiated price caps for specific Medicare Part D drugs remain in effect and are scheduled to take effect in 2026.
Primary Sources
FactCheck.org rated claims that Trump reversed all Biden drug pricing measures as false, noting that negotiated Medicare drug prices remain intact
USA Today confirmed that Medicare drug price caps negotiated under the Inflation Reduction Act were not reversed by Trump's executive order
Snopes rated as mostly true that Trump's order walked back some Biden-era drug pricing efforts, but noted distinctions between what was paused versus reversed
Evidence Supporting the Claim
- Trump signed an executive order in January 2025 that paused or rolled back some Biden-era drug pricing regulations
- The executive order affected certain regulatory actions related to prescription drug pricing taken during the Biden administration
Evidence Against / Context
- The negotiated Medicare prescription drug price caps established under the Inflation Reduction Act remain in effect and were not reversed by Trump's executive order
- FactCheck.org explicitly rated claims that Trump reversed Biden's drug cost measures as false
- USA Today confirmed that Medicare drug price caps negotiated under the Inflation Reduction Act continue to remain in place
- The negotiated prices for specific Medicare Part D drugs are still scheduled to take effect in 2026 as originally planned
- The claim specifically references 'negotiated' cost caps for Medicare and Medicaid, which were not reversed
Timeline
President Biden signed the Inflation Reduction Act, which included provisions for Medicare to negotiate prescription drug prices
Trump signed an executive order affecting some Biden-era drug pricing regulations
Negotiated Medicare prescription drug prices scheduled to take effect
What This Means
Structured interpretation — not opinion
Key takeaway 1
Trump's executive order affected some aspects of Biden-era drug pricing policy, but did not reverse the core Medicare drug price negotiation program established by the Inflation Reduction Act
Key takeaway 2
The distinction between pausing certain regulatory actions and reversing negotiated price caps is significant, as the negotiated prices for specific Medicare drugs remain intact
Key takeaway 3
Claims that Trump reversed negotiated Medicare and Medicaid drug cost caps are not supported by available evidence from multiple fact-checking organizations
Related Claims in health
“The FDA was changing leucovorin's label because it could help 'hundreds of thousands' of children with autism”
FDA Commissioner Marty Makary announced in September 2025 that the agency would change leucovorin's label to reflect potential benefits for some children with autism and cerebral folate deficiency. However, the FDA later clarified the label change applied to a rare subset of patients with a specific metabolic condition, not hundreds of thousands of children, and the agency disputed characterizations that overstated the scope of the change.
“The Trump administration enacted a 6-month moratorium on Minnesota Medicaid payments”
On February 27, 2026, the Trump administration implemented a six-month moratorium on federal Medicaid payments to Minnesota through the Centers for Medicare and Medicaid Services. The action was taken in response to Minnesota's policies regarding undocumented immigrants' access to state healthcare programs, which federal officials characterized as violations of federal law.
“90% of health care spending treats chronic disease”
The claim that 90% of healthcare spending treats chronic disease is an overstatement of the actual figures. Federal health agencies report that chronic diseases account for approximately 75-90% of healthcare spending, with the most commonly cited figure from the Centers for Disease Control and Prevention being 90% of the nation's $4.5 trillion in annual healthcare expenditures, though this appears to include broadly defined chronic conditions and may represent an upper-bound estimate.